What type of medication is Xolair (omalizumab)?

Xolair (omalizumab) is classified as an anti-IgE medication. It works by binding to immunoglobulin E (IgE) antibodies in the bloodstream, preventing them from attaching to mast cells and basophils. This action inhibits the release of inflammatory mediators such as histamines, which play a significant role in allergic responses and asthma exacerbations.

By reducing the effects of IgE, Xolair helps to decrease the incidence of asthma attacks and alleviate symptoms in patients with moderate to severe allergic asthma that is inadequately controlled with conventional therapy. This targeted mechanism makes it an effective option for managing allergies and some forms of asthma.

The other choices represent different classes of medications that serve various purposes. Anti-IL5 medications target eosinophils to reduce inflammation in severe asthma, leukotriene receptor antagonists block the effects of leukotrienes to decrease airway inflammation, and short-acting bronchodilators work by relaxing the muscles around the airways to relieve acute symptoms. However, these medications operate through different mechanisms and do not directly inhibit IgE, distinguishing them from Xolair.